CCM
Camber Capital Management Portfolio holdings
AUM
$718M
1-Year Est. Return
8.19%
This Fund
S&P 500
1 Year Est. Return
-8.19%
AUM
$718M
AUM Growth
-$885M
(-55%)
Holding
35
Top Buys
| 1 | +$42.6M | |
| 2 | +$39.7M | |
| 3 | +$38.2M | |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$15.7M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$5.89M |
Top Sells
| 1 | +$121M | |
| 2 | +$106M | |
| 3 | +$87.9M | |
| 4 |
CVS Health
CVS
|
+$78.7M |
| 5 |
PTC Therapeutics
PTCT
|
+$76.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Qiagen
QGEN
$10.3B
| – | – |
-1,400,000
|
|
||
27
State Street SPDR S&P 500 ETF Trust
SPY
$699B
| – | – |
0
|
|
||
28
Sarepta Therapeutics
SRPT
$1.76B
| – | – |
-800,000
|
|
||
29
10x Genomics
TXG
$2.94B
| – | – |
-1,000,000
|
|
||
30
State Street SPDR S&P Biotech ETF
XBI
$8.13B
| – | – |
0
|
|
||
31
Cigna
CI
$76.4B
| – | – |
-200,000
|
|
||
32
Genmab
GMAB
$18.1B
| – | – |
-50,000
|
|
||
33
GSK
GSK
$119B
| – | – |
0
|
|
||
34
MoonLake Immunotherapeutics
MLTX
$1.24B
| – | – |
-441,000
|
|
||
|
35
PTC Therapeutics
PTCT
$5.47B
| – | – |
-1,500,000
|
|